NSAID-Enhanced Reduced-Dose Decongestant and Antihistamine Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for rhinitis, which combine decongestants and antihistamines, often cause side effects such as irritability and sedation due to varying sensitivities, and non-steroidal anti-inflammatory drugs (NSAIDs) do not adequately alleviate symptoms without side effects.
Innovation Solution
A pharmaceutical composition containing reduced amounts of decongestants and antihistamines in combination with a normal strength NSAID, such as ibuprofen, to enhance efficacy while minimizing side effects, with the decongestant or antihistamine present at less than 75% of their approved doses relative to the NSAID.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional products use higher doses of decongestants and antihistamines, then symptom relief is improved, but side effects such as irritability and sedation increase
Solution Approach 1:
The patent changes the dosage parameters by reducing decongestant and antihistamine doses to less than 75% of approved doses while maintaining NSAID at normal strength, thereby achieving similar symptom relief with reduced side effects
Solution Approach 2:
The patent creates a composite pharmaceutical formulation combining NSAID with reduced-dose decongestant and antihistamine, where the NSAID enhances the efficacy of the reduced-dose components, allowing effective symptom relief with lower doses of the potentially harmful ingredients
2Reliability
If decongestant and antihistamine are combined in a single dosage unit, then more complete symptom relief is achieved, but individual sensitivity variations cause irritability and sedation
Solution Approach 1:
The patent adjusts the dosage parameters of decongestant and antihistamine to reduced levels (less than 75% of approved doses), making the combination more tolerable for individuals with varying sensitivities while maintaining complete symptom relief through NSAID enhancement
3Object-generated harmful factors
If NSAID is used alone to treat rhinitis symptoms, then fewer side effects occur, but symptom relief is inadequate
Solution Approach 1:
The patent merges NSAID with reduced-dose decongestant and antihistamine in a single formulation, where the NSAID provides a foundation of symptom relief with fewer side effects, and the reduced-dose components supplement additional relief without causing the side effects associated with full-dose monotherapy
Data Source
AI summary
The present invention is directed to a pharmaceutical composition and method for the treatment of rhinitis and cold-like symptoms which includes a non-steroidal anti-inflammatory drug (NSAID), a decongestant, and an antihistamine. It has been found that an NSAID enhances the activity of a decongestant and an anti-histamine, thus permitting a reduction in either or both in administration of separate dosage forms. The same enhancement can also occur with an anti-tussitive. Thus, the effective amount of the decongestant or the antihistamine or both is less than about 75% of an amount present in an approved dose of the decongestant or the antihistamine, or both, relative to an amount of the NSAID corresponding to about 100% of the amount present in a normal strength dosage form of the NSAID.